Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI

Next Previous
Trial Profile

An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadobutrol (Primary)
  • Indications Breast cancer
  • Focus Diagnostic use; Registrational
  • Acronyms GEMMA 1
  • Sponsors Bayer

    • Most Recent Events

    • 25 Jun 2014 New trial record
    • 12 Jun 2014 Results of this and another trial (CT profile 246109) have been reported in a Bayer media release.
    • 12 Jun 2014 According to a Bayer media release, gadobutrol was approved to assess the presence and extent of malignant breast disease on the basis of the results from this and another trial (see CTI profile 246109).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top